Skip to main content
SpringerLink
Log in

Neuroblastoma

  • Living reference work entry
  • First Online:
Pediatric Surgical Oncology

  • 77 Accesses

Abstract

Neurobastoma is a small round blue cell tumor that uniquely has the ability to mature and regress, either spontaneously or in response to treatment, or conversely, become undifferentiated and highly malignant. Due to this, treatment ranges from simple observation in select infants to aggressive multimodal therapy including chemotherapy, surgical resection, myeloablative therapy with stem cell rescue, radiation therapy, and immunotherapy. Tumor staging and risk classification for neuroblastoma continue to evolve as new genomic prognostic markers are identified and efforts continue to unify risk-based treatment strategies worldwide. Surgical resection plays an important role in the local control of neuroblastoma. In patient with high-risk neuroblastoma, neoadjuvant chemotherapy followed by primary tumor resection of ≥90% has been shown to improve local control and may improve both event free and overall survival.

In low- and intermediate-risk patients, survival is high and therefore, efforts are focused on therapy reductions in order to diminish treatment related complications. Unfortunately, the majority of neuroblastoma patients present with high-risk disease in which outcomes have improved but remain poor.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Similar content being viewed by others

References

  1. Steliarova-Foucher E, Colombet M, Ries LAG, Moreno F, Dolya A, Bray F, et al. International incidence of childhood cancer, 2001–10: a population-based registry study. Lancet Oncol. 2017;18(6):719–31.

    Article  Google Scholar 

  2. Yan P, Qi F, Bian L, Xu Y, Zhou J, Hu J, et al. Comparison of incidence and outcomes of neuroblastoma in children, adolescents, and adults in the United States: a Surveillance, Epidemiology, and End Results (SEER) Program Population Study. Med Sci Monit Int Med J Exp Clin Res. 2020;26:e927218.

    Google Scholar 

  3. Georgakis MK, Dessypris N, Baka M, Moschovi M, Papadakis V, Polychronopoulou S, et al. Neuroblastoma among children in Southern and Eastern European cancer registries: variations in incidence and temporal trends compared to US. Int J Cancer. 2018;142(10):1977–85.

    Article  CAS  Google Scholar 

  4. van Heerden J, Kruger M. Management of neuroblastoma in limited-resource settings. World J Clin Oncol. 2020;11(8):629–43. https://doi.org/10.5306/wjco.v11.i8.629. PMID: 32879849; PMCID: PMC7443833.

    Article  Google Scholar 

  5. Stiller CA, Parkin DM. International variations in the incidence of neuroblastoma. Int J Cancer. 1992;52(4):538–43.

    Article  CAS  Google Scholar 

  6. Neuroblastoma Treatment (PDQ®) – Health Professional Version – National Cancer Institute [Internet]. 2021 [cited 2021 Sep 28]. Available from: https://www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdf

  7. Mossé YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008;455(7215):930–5.

    Article  Google Scholar 

  8. Mosse YP, Laudenslager M, Khazi D, Carlisle AJ, Winter CL, Rappaport E, et al. Germline PHOX2B mutation in hereditary neuroblastoma. Am J Hum Genet. 2004;75(4):727–30.

    Article  CAS  Google Scholar 

  9. Mosse Y, Greshock J, King A, Khazi D, Weber BL, Maris JM. Identification and high-resolution mapping of a constitutional 11q deletion in an infant with multifocal neuroblastoma. Lancet Oncol. 2003;4(12):769–71.

    Article  CAS  Google Scholar 

  10. Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am. 2010;24(1):65–86.

    Article  Google Scholar 

  11. Russo C, Cohn SL, Petruzzi MJ, de Alarcon PA. Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group. Med Pediatr Oncol. 1997;28(4):284–8.

    Article  CAS  Google Scholar 

  12. Rudnick E, Khakoo Y, Antunes NL, Seeger RC, Brodeur GM, Shimada H, et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children’s Cancer Group Study. Med Pediatr Oncol. 2001;36(6):612–22.

    Article  CAS  Google Scholar 

  13. Ambros IM, Zellner A, Roald B, Amann G, Ladenstein R, Printz D, et al. Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma. N Engl J Med. 1996;334(23):1505–11.

    Article  CAS  Google Scholar 

  14. Ambros IM, Zellner A, Stock C, Amann G, Gadner H, Ambros PF. Proof of the reactive nature of the Schwann cell in neuroblastoma and its clinical implications. Prog Clin Biol Res. 1994;385:331–7.

    CAS  Google Scholar 

  15. Beckwith JB, Perrin EV. In situ neuroblastomas: a contribution to the natural history of neural crest tumors. Am J Pathol. 1963;43:1089–104.

    CAS  Google Scholar 

  16. Shimada H, Chatten J, Newton WA, Sachs N, Hamoudi AB, Chiba T, et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst. 1984;73(2):405–16.

    Article  CAS  Google Scholar 

  17. Peuchmaur M, d’Amore ESG, Joshi VV, Hata J, Roald B, Dehner LP, et al. Revision of the international neuroblastoma pathology classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer. 2003;98(10):2274–81.

    Article  Google Scholar 

  18. Irwin MS, Naranjo A, Zhang FF, Cohn SL, London WB, Gastier-Foster JM, et al. Revised neuroblastoma risk classification system: a report from the Children’s Oncology Group. J Clin Oncol. 2021;39(29):3229–41. https://doi.org/10.1200/JCO.21.00278. Epub 2021 Jul 28. PMID: 34319759.

    Article  CAS  Google Scholar 

  19. De Bernardi B, Gambini C, Haupt R, Granata C, Rizzo A, Conte M, et al. Retrospective study of childhood ganglioneuroma. J Clin Oncol. 2008;26(10):1710–6.

    Article  Google Scholar 

  20. Brodeur GM, Hayes FA, Green AA, Casper JT, Wasson J, Wallach S, et al. Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients. Cancer Res. 1987;47(16):4248–53.

    CAS  Google Scholar 

  21. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984;224(4653):1121–4.

    Article  CAS  Google Scholar 

  22. Liang WH, Federico SM, London WB, Naranjo A, Irwin MS, Volchenboum SL, et al. Tailoring therapy for children with neuroblastoma on the basis of risk group classification: past, present, and future. JCO Clin Cancer Inform. 2020;4:895–905.

    Article  Google Scholar 

  23. Santiago T, Polanco AC, Fuentes-Alabi S, Hayes C, Orellana E, Gomero B, et al. Multinational retrospective central pathology review of neuroblastoma: lessons learned to establish a regional pathology referral center in resource-limited settings. Arch Pathol Lab Med. 2021;145(2):214–21.

    Article  CAS  Google Scholar 

  24. Santiago T, Tarek N, Boulos F, Hayes C, Jeha S, Raimondi S, et al. Correlation between MYCN gene status and MYCN protein expression in neuroblastoma: a pilot study to propose the use of MYCN immunohistochemistry in limited-resource areas. J Glob Oncol. 2019;5:1–7.

    CAS  Google Scholar 

  25. Schleiermacher G, Michon J, Ribeiro A, Pierron G, Mosseri V, Rubie H, et al. Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study). Br J Cancer. 2011;105(12):1940–8.

    Article  CAS  Google Scholar 

  26. Carén H, Kryh H, Nethander M, Sjöberg RM, Träger C, Nilsson S, et al. High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci U S A. 2010;107(9):4323–8.

    Article  Google Scholar 

  27. Schleiermacher G, Janoueix-Lerosey I, Ribeiro A, Klijanienko J, Couturier J, Pierron G, et al. Accumulation of segmental alterations determines progression in neuroblastoma. J Clin Oncol. 2010;28(19):3122–30.

    Article  Google Scholar 

  28. Fong CT, Dracopoli NC, White PS, Merrill PT, Griffith RC, Housman DE, et al. Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification. Proc Natl Acad Sci U S A. 1989;86(10):3753–7.

    Article  CAS  Google Scholar 

  29. Attiyeh EF, London WB, Mossé YP, Wang Q, Winter C, Khazi D, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med. 2005;353(21):2243–53.

    Article  CAS  Google Scholar 

  30. Takayama H, Suzuki T, Mugishima H, Fujisawa T, Ookuni M, Schwab M, et al. Deletion mapping of chromosomes 14q and 1p in human neuroblastoma. Oncogene. 1992;7(6):1185–9.

    CAS  Google Scholar 

  31. Carén H, Abel F, Kogner P, Martinsson T. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J. 2008;416(2):153–9.

    Article  Google Scholar 

  32. Carpenter EL, Mossé YP. Targeting ALK in neuroblastoma–preclinical and clinical advancements. Nat Rev Clin Oncol. 2012;9(7):391–9.

    Article  CAS  Google Scholar 

  33. Redaelli S, Ceccon M, Zappa M, Sharma GG, Mastini C, Mauri M, et al. Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer. Cancer Res. 2018;78(24):6866–80.

    Article  CAS  Google Scholar 

  34. Liu T, Merguerian MD, Rowe SP, Pratilas CA, Chen AR, Ladle BH. Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed ALK F1174L-mutated neuroblastoma. Cold Spring Harb Mol Case Stud. 2021;7(4):a006064.

    Article  CAS  Google Scholar 

  35. Chen W, Jin D, Shi Y, Zhang Y, Zhou H, Li G. The underlying mechanisms of lorlatinib penetration across the blood-brain barrier and the distribution characteristics of lorlatinib in the brain. Cancer Med. 2020;9(12):4350–9.

    Article  CAS  Google Scholar 

  36. Cheung NKV, Zhang J, Lu C, Parker M, Bahrami A, Tickoo SK, et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA. 2012;307(10):1062–71.

    Article  CAS  Google Scholar 

  37. Koneru B, Lopez G, Farooqi A, Conkrite KL, Nguyen TH, Macha SJ, et al. Telomere maintenance mechanisms define clinical outcome in high-risk neuroblastoma. Cancer Res. 2020;80(12):2663–75.

    Article  CAS  Google Scholar 

  38. Joshi VV, Cantor AB, Brodeur GM, Look AT, Shuster JJ, Altshuler G, et al. Correlation between morphologic and other prognostic markers of neuroblastoma. A study of histologic grade, DNA index, N-myc gene copy number, and lactic dehydrogenase in patients in the Pediatric Oncology Group. Cancer. 1993;71(10):3173–81.

    Article  CAS  Google Scholar 

  39. Moroz V, Machin D, Hero B, Ladenstein R, Berthold F, Kao P, et al. The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: a report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2020;67(8):e28359.

    Article  CAS  Google Scholar 

  40. Silber JH, Evans AE, Fridman M. Models to predict outcome from childhood neuroblastoma: the role of serum ferritin and tumor histology. Cancer Res. 1991;51(5):1426–33.

    CAS  Google Scholar 

  41. Fitzgibbon MC, Tormey WP. Paediatric reference ranges for urinary catecholamines/metabolites and their relevance in neuroblastoma diagnosis. Ann Clin Biochem. 1994;31(Pt 1):1–11.

    Article  Google Scholar 

  42. Ng YY, Kingston JE. The role of radiology in the staging of neuroblastoma. Clin Radiol. 1993;47(4):226–35.

    Article  CAS  Google Scholar 

  43. Siegel MJ, Ishwaran H, Fletcher BD, Meyer JS, Hoffer FA, Jaramillo D, et al. Staging of neuroblastoma at imaging: report of the radiology diagnostic oncology group. Radiology. 2002;223(1):168–75.

    Article  Google Scholar 

  44. Paltiel HJ, Gelfand MJ, Elgazzar AH, Washburn LC, Harris RE, Masters PR, et al. Neural crest tumors: I-123 MIBG imaging in children. Radiology. 1994;190(1):117–21.

    Article  CAS  Google Scholar 

  45. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11(8):1466–77.

    Article  CAS  Google Scholar 

  46. Brisse HJ, McCarville MB, Granata C, Krug KB, Wootton-Gorges SL, Kanegawa K, et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group project. Radiology. 2011;261(1):243–57.

    Article  Google Scholar 

  47. Cohn SL, Pearson ADJ, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2009;27(2):289–97.

    Article  Google Scholar 

  48. Nuchtern JG, London WB, Barnewolt CE, Naranjo A, McGrady PW, Geiger JD, et al. A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children’s Oncology Group study. Ann Surg. 2012;256(4):573–80.

    Article  Google Scholar 

  49. Twist CJ, Schmidt ML, Naranjo A, London WB, Tenney SC, Marachelian A, et al. Maintaining outstanding outcomes using response- and biology-based therapy for intermediate-risk neuroblastoma: a report from the Children’s Oncology Group study ANBL0531. J Clin Oncol. 2019;37(34):3243–55.

    Article  CAS  Google Scholar 

  50. Park JR, Kreissman SG, London WB, Naranjo A, Cohn SL, Hogarty MD, et al. Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a randomized clinical trial. JAMA. 2019;322(8):746–55.

    Article  Google Scholar 

  51. Hank JA, Surfus J, Gan J, Chew TL, Hong R, Tans K, et al. Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro. J Immunother Emphas Tumor Immunol. 1994;15(1):29–37.

    Article  CAS  Google Scholar 

  52. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363(14):1324–34.

    Article  CAS  Google Scholar 

  53. London WB, Castel V, Monclair T, Ambros PF, Pearson ADJ, Cohn SL, et al. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol. 2011;29(24):3286–92.

    Article  Google Scholar 

  54. Paulino AC. Palliative radiotherapy in children with neuroblastoma. Pediatr Hematol Oncol. 2003;20(2):111–7.

    Article  CAS  Google Scholar 

  55. Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, et al. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncol. 2017;18(7):946–57.

    Article  CAS  Google Scholar 

  56. Perez CA, Matthay KK, Atkinson JB, Seeger RC, Shimada H, Haase GM, et al. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a Children’s Cancer Group study. J Clin Oncol. 2000;18(1):18–26.

    Article  CAS  Google Scholar 

  57. Nishihira H, Toyoda Y, Tanaka Y, Ijiri R, Aida N, Takeuchi M, et al. Natural course of neuroblastoma detected by mass screening: s 5-year prospective study at a single institution. J Clin Oncol. 2000;18(16):3012–7.

    Article  CAS  Google Scholar 

  58. Davidoff AM, Corey BL, Hoffer FA, Santana VM, Furman WL, Shochat SJ. Radiographic assessment of resectability of locoregional disease in children with high-risk neuroblastoma during neoadjuvant chemotherapy. Pediatr Blood Cancer. 2005;44(2):158–62.

    Article  Google Scholar 

  59. Simon T, Hero B, Benz-Bohm G, von Schweinitz D, Berthold F. Review of image defined risk factors in localized neuroblastoma patients: results of the GPOH NB97 trial. Pediatr Blood Cancer. 2008;50(5):965–9.

    Article  Google Scholar 

  60. Günther P, Holland-Cunz S, Schupp CJ, Stockklausner C, Hinz U, Schenk JP. Significance of image-defined risk factors for surgical complications in patients with abdominal neuroblastoma. Eur J Pediatr Surg. 2011;21(5):314–7.

    Article  Google Scholar 

  61. Yoneda A, Nishikawa M, Uehara S, Oue T, Usui N, Inoue M, et al. Can image-defined risk factors predict surgical complications in localized neuroblastoma? Eur J Pediatr Surg. 2016;26(1):117–22.

    Google Scholar 

  62. Mansfield SA, McCarville MB, Lucas JT, Krasin MJ, Federico SM, Santana VM, et al. Impact of neoadjuvant chemotherapy on image-defined risk factors in high-risk neuroblastoma. Ann Surg Oncol. 2021;29:661–70.

    Article  Google Scholar 

  63. DuBois SG, Kalika Y, Lukens JN, Brodeur GM, Seeger RC, Atkinson JB, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol. 1999;21(3):181–9.

    Article  CAS  Google Scholar 

  64. von Allmen D, Davidoff AM, London WB, Van Ryn C, Haas-Kogan DA, Kreissman SG, et al. Impact of extent of resection on local control and survival in patients From the COG A3973 study with high-risk neuroblastoma. J Clin Oncol. 2017;35(2):208–16.

    Article  Google Scholar 

  65. Holmes K, Pötschger U, Pearson ADJ, Sarnacki S, Cecchetto G, Gomez-Chacon J, et al. Influence of surgical excision on the survival of patients with stage 4 high-risk neuroblastoma: a report from the HR-NBL1/SIOPEN study. J Clin Oncol. 2020;38(25):2902–15.

    Article  Google Scholar 

  66. Shorter NA, Davidoff AM, Evans AE, Ross AJ, Zeigler MM, O’Neill JA. The role of surgery in the management of stage IV neuroblastoma: a single institution study. Med Pediatr Oncol. 1995;24(5):287–91.

    Article  CAS  Google Scholar 

  67. Kiely EM. The surgical challenge of neuroblastoma. J Pediatr Surg. 1994;29(2):128–33.

    Article  CAS  Google Scholar 

  68. Azizkhan RG, Shaw A, Chandler JG. Surgical complications of neuroblastoma resection. Surgery. 1985;97(5):514–7.

    CAS  Google Scholar 

  69. Schmidt ML, Lukens JN, Seeger RC, Brodeur GM, Shimada H, Gerbing RB, et al. Biologic factors determine prognosis in infants with stage IV neuroblastoma: a prospective Children’s Cancer Group study. J Clin Oncol. 2000;18(6):1260–8.

    Article  CAS  Google Scholar 

  70. van Heerden J, Kruger M, Esterhuizen TM, van Zyl A, Hendricks M, Cox S, Mangray H, Poole J, Naidu G, Büchner A, de Villiers M, du Plessis J, van Emmenes B, Matthews E, Manickchund Y, Harrison DS. The pre-surgical factors that determine the decision to proceed to resection in children diagnosed with high-risk neuroblastoma in a resource limited setting, Pediatric Hematology and Oncology. 2022. https://doi.org/10.1080/08880018.2022.2137610

  71. Gurria JP, Malek MM, Heaton TE, Gehred A, Lautz TB, Rhee DS, et al. Minimally invasive surgery for abdominal and thoracic neuroblastic tumors: a systematic review by the APSA Cancer committee. J Pediatr Surg. 2020;55(11):2260–72.

    Article  Google Scholar 

  72. Berthold F, Utsch S, Holschneider AM. The impact of preoperative chemotherapy on resectability of primary tumour and complication rate in metastatic neuroblastoma. Z Kinderchir. 1989;44(1):21–4.

    CAS  Google Scholar 

  73. Rich BS, McEvoy MP, Kelly NE, Oh E, Abramson SJ, Price AP, et al. Resectability and operative morbidity after chemotherapy in neuroblastoma patients with encasement of major visceral arteries. J Pediatr Surg. 2011;46(1):103–7.

    Article  Google Scholar 

  74. Parikh NS, Howard SC, Chantada G, Israels T, Khattab M, Alcasabas P, et al. SIOP-PODC adapted risk stratification and treatment guidelines: recommendations for neuroblastoma in low- and middle-income settings. Pediatr Blood Cancer. 2015;62(8):1305–16. https://doi.org/10.1002/pbc.25501. Epub 2015 Mar 21. PMID: 25810263; PMCID: PMC5132052

    Article  Google Scholar 

  75. Arora RS, Eden T, Pizer B. The problem of treatment abandonment in children from developing countries with cancer. Pediatr Blood Cancer. 2007;49(7):941–6.

    Article  Google Scholar 

  76. Woods WG, Gao RN, Shuster JJ, Robison LL, Bernstein M, Weitzman S, et al. Screening of infants and mortality due to neuroblastoma. N Engl J Med. 2002;346(14):1041–6.

    Article  Google Scholar 

  77. Schilling FH, Spix C, Berthold F, Erttmann R, Fehse N, Hero B, et al. Neuroblastoma screening at one year of age. N Engl J Med. 2002;346(14):1047–53.

    Article  Google Scholar 

  78. Nickerson HJ, Matthay KK, Seeger RC, Brodeur GM, Shimada H, Perez C, et al. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children’s Cancer Group study. J Clin Oncol. 2000;18(3):477–86.

    Article  CAS  Google Scholar 

  79. Katzenstein HM, Kent PM, London WB, Cohn SL. Treatment and outcome of 83 children with intraspinal neuroblastoma: the Pediatric Oncology Group experience. J Clin Oncol. 2001;19(4):1047–55.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pediatric Surgery, Medical College of Wisconsin/Children’s Wisconsin, Milwaukee, WI, USA

    Dave R. Lal

  2. St. Jude Children’s Research Hospital, Memphis, TN, USA

    Andrew M. Davidoff

Authors
  1. Dave R. Lal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew M. Davidoff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dave R. Lal .

Editor information

Editors and Affiliations

  1. University of Oxford, Oxford, UK

    Kokila Lakhoo

  2. St. Jude Children's Research Hospital, Memphis, TN, USA

    Abdelhafeez H. Abdelhafeez

  3. Federal University of Sao Paulo, Sao Paulo, Brazil

    Simone Abib

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Lal, D.R., Davidoff, A.M. (2023). Neuroblastoma. In: Lakhoo, K., Abdelhafeez, A.H., Abib, S. (eds) Pediatric Surgical Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-71113-9_107-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-71113-9_107-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-71113-9

  • Online ISBN: 978-3-030-71113-9

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation